Company intelligence / Profile preview

Adastra Pharmaceuticals

Princeton, New Jersey, United Statesadastrarx.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Adastra Pharmaceuticals was a clinical-stage biopharmaceutical company focused on developing small molecule therapies for aggressive cancers. Its lead program zotiraciclib targeted multiple cyclin-dependent kinases and reached Phase I/II in high-grade gliomas before being acquired by Cothera Bioscience in October 2021. Another candidate, apricoxib targeting COX‑2 for HER2-positive breast cancer, was discontinued. The company appears to have ceased independent R&D following the asset transfer[1][5][6].

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

zotiraciclib

Phase 1

Indications: High-grade gliomas

Partnerships

European Organisation for Research and Treatment of Cancer (EORTC) as trial collaborator[5]

Beyond the preview

Go deeper on Adastra Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adastra Pharmaceuticals.